Literature DB >> 27613493

Drug exposure and clinical effect of transdermal mirtazapine in healthy young cats: a pilot study.

Kellyi K Benson1, Lara B Zajic1, Paula K Morgan1, Sarah R Brown1, Ryan J Hansen1, Paul J Lunghofer1, Luke A Wittenburg1, Daniel L Gustafson1, Jessica M Quimby1.   

Abstract

Objectives The objective of this study was to measure drug exposure and clinical effects after administration of transdermal mirtazapine (TMZ) in healthy cats. Methods Phase I: seven healthy research cats received (1) 3.75 mg and 7.5 mg TMZ once aurally with 48 h serum sampling (serum samples were obtained via the jugular catheter at 0, 0.5, 1, 2, 5, 9, 12, 24, 36 and 48 h); (2) 7.5 mg TMZ and placebo daily aurally for 6 days then 48 h serum sampling; (3) 1.88 mg mirtazapine orally once with serum sampling at 1, 4 and 8 h. Phase II: 20 client-owned cats were enrolled in a randomized, double-blind, placebo-controlled, three-way crossover clinical effect study. Treatments consisted of 6 days of aural 7.5 mg TMZ or placebo gel at home, and 1.88 mg mirtazapine orally once in the clinic. Owners documented appetite, rate of food ingestion, begging activity and vocalization daily at home. On day 6, food consumed, activity and vocalization were documented in hospital, and trough and peak serum mirtazapine levels were obtained. Serum mirtazapine and gel concentrations were measured using liquid chromatography/tandem mass spectrometry. Results Phase I: administration of TMZ achieved measureable serum mirtazapine concentrations. Area under the curve0-48 of multidose 7.5 mg TMZ was significantly higher than single-dose 1.88 mg oral mirtazapine (OMZ) ( P = 0.02). Phase II: client-owned cats administered TMZ had a significant increase in appetite ( P = 0.003), rate of food ingestion ( P = 0.002), activity ( P = 0.002), begging ( P = 0.002) and vocalization ( P = 0.002) at home. In hospital there was a significant increase in food ingested with both TMZ and OMZ compared with placebo ( P <0.05). Gel concentrations ranged from 87%-119% of target dose. Conclusions and relevance TMZ 7.5 mg daily achieves measureable serum concentrations and produces significant appetite stimulation despite variance in compounded gel concentrations, but side effects denote a lower dose is indicated.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27613493      PMCID: PMC5647142          DOI: 10.1177/1098612X16667168

Source DB:  PubMed          Journal:  J Feline Med Surg        ISSN: 1098-612X            Impact factor:   2.015


  13 in total

1.  Ghrelin's Orexigenic Effect Is Modulated via a Serotonin 2C Receptor Interaction.

Authors:  Harriët Schellekens; Pablo N De Francesco; Dalia Kandil; Wessel F Theeuwes; Triona McCarthy; Wesley E P A van Oeffelen; Mario Perelló; Linda Giblin; Timothy G Dinan; John F Cryan
Journal:  ACS Chem Neurosci       Date:  2015-03-10       Impact factor: 4.418

Review 2.  Drug compounding for veterinary patients.

Authors:  Mark G Papich
Journal:  AAPS J       Date:  2005-09-22       Impact factor: 4.009

3.  The pharmacokinetics of mirtazapine in cats with chronic kidney disease and in age-matched control cats.

Authors:  J M Quimby; D L Gustafson; K F Lunn
Journal:  J Vet Intern Med       Date:  2011-08-30       Impact factor: 3.333

Review 4.  Veterinary compounding in small animals: a clinical pharmacologist's perspective.

Authors:  Dawn Merton Boothe
Journal:  Vet Clin North Am Small Anim Pract       Date:  2006-09       Impact factor: 2.093

5.  Studies on the pharmacokinetics and pharmacodynamics of mirtazapine in healthy young cats.

Authors:  J M Quimby; D L Gustafson; B J Samber; K F Lunn
Journal:  J Vet Pharmacol Ther       Date:  2010-10-24       Impact factor: 1.786

6.  Treatment of feline hypertension with transdermal amlodipine: a pilot study.

Authors:  Scott Roderick Helms
Journal:  J Am Anim Hosp Assoc       Date:  2007 May-Jun       Impact factor: 1.023

7.  Impact of the blood sampling site on time-concentration drug profiles following intravenous or buccal drug administration.

Authors:  A R Hedges; B H Pypendop; Y Shilo; S D Stanley; J E Ilkiw
Journal:  J Vet Pharmacol Ther       Date:  2014-04       Impact factor: 1.786

8.  Bioavailability of transdermal methimazole in a pluronic lecithin organogel (PLO) in healthy cats.

Authors:  S B Hoffman; A R Yoder; L A Trepanier
Journal:  J Vet Pharmacol Ther       Date:  2002-06       Impact factor: 1.786

9.  Cancer chemotherapy and cachexia: mirtazapine and olanzapine are 5-HT3 antagonists with good antinausea effects.

Authors:  R E Kast; K F Foley
Journal:  Eur J Cancer Care (Engl)       Date:  2007-07       Impact factor: 2.520

Review 10.  The role of hypothalamic H1 receptor antagonism in antipsychotic-induced weight gain.

Authors:  Meng He; Chao Deng; Xu-Feng Huang
Journal:  CNS Drugs       Date:  2013-06       Impact factor: 5.749

View more
  7 in total

1.  Comparison of Effects of Capromorelin and Mirtazapine on Appetite in New Zealand White Rabbits (Oryctolagus cuniculus).

Authors:  Janna Mh Draper; Daniel J Savson; Elizabeth S Lavin; Erica R Feldman; Bhupinder Singh; Manuel Martin-Flores; Erin K Daugherity
Journal:  J Am Assoc Lab Anim Sci       Date:  2022-08-18       Impact factor: 1.706

2.  A double-blind, placebo-controlled, randomized study to evaluate the weight gain drug, mirtazapine transdermal ointment, in cats with unintended weight loss.

Authors:  Melinda Poole; Jessica M Quimby; Tianhua Hu; Daizie Labelle; William Buhles
Journal:  J Vet Pharmacol Ther       Date:  2018-12-02       Impact factor: 1.786

3.  Assessment of compounded transdermal mirtazapine as an appetite stimulant in cats with chronic kidney disease.

Authors:  Jessica M Quimby; Kellyi K Benson; Stacie C Summers; Ashlie Saffire; Andrea K Herndon; Shasha Bai; Daniel L Gustafson
Journal:  J Feline Med Surg       Date:  2019-06-04       Impact factor: 2.015

Review 4.  Drug-Dosing Adjustment in Dogs and Cats with Chronic Kidney Disease.

Authors:  Francesca De Santis; Andrea Boari; Francesco Dondi; Paolo Emidio Crisi
Journal:  Animals (Basel)       Date:  2022-01-21       Impact factor: 2.752

5.  The pharmacokinetics of gabapentin in cats.

Authors:  Derek Adrian; Mark G Papich; Ronald Baynes; Emma Stafford; B Duncan X Lascelles
Journal:  J Vet Intern Med       Date:  2018-10-11       Impact factor: 3.333

6.  Serum levetiracetam concentrations after transdermal levetiracetam administration, 3 times daily, to healthy cats.

Authors:  Casey Smith; Heidi L Barnes Heller; Nicole Reif; Matthew Van Hesteren; Jennifer M Reinhart
Journal:  J Vet Intern Med       Date:  2019-01-21       Impact factor: 3.333

7.  Appetite Stimulant and Anti-Emetic Effect of Mirtazapine Transdermal Ointment in Cats Affected by Lymphoma Following Chemotherapy Administration: A Multi-Centre Retrospective Study.

Authors:  Livia Ferro; Stefano Ciccarelli; Giacomo Stanzani; Lisa Nappi; Francesca Angelini; Chiara Leo
Journal:  Animals (Basel)       Date:  2022-01-09       Impact factor: 2.752

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.